Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen

Annals of Oncology

Volumn 13, Issue 9, 2002, Pages 1378-1386

  Arriagada, R ^a   Spielmann, M ^a   Koscielny, S ^a   Le Chevalier, T ^a   Delozier, T ^b   Ducourtieux, M ^c   Tursz, T ^a   Hill, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Centre Regional Francoise Baclesse   (France)

^c Instituto de Radiomedicina Santiago   (Chile)

Author keywords

Adjuvant chemotherapy; Adjuvant tamoxifen; Early breast cancer; Postmenopausal patients; Randomized trial

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MITOXANTRONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EARLY CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; FRANCE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL RATE; TAMOXIFEN; TREATMENT FAILURE;

EID: 0036737602     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf299     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group. The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28 896 women. N Engl J Med 1988; 319: 1681-1692.
2. Contesso G, Mouriesse H, Friedman S et al. The importance of histologic grade in long-term prognosis of breast cancer. A study of 1010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987; 5: 1378-1386.
3. Delozier T, Spielmann M, Mace-Lesec'h J et al. Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment. J Clin Oncol 2000; 18: 3507-3512.
4. Arriagada R, Rutqvist LE, Kramar A et al. Competing risks determining event-free survival in early breast cancer. Br J Cancer 1992; 66: 951-957.
5. Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer, Volume 1. Worldwide Evidence 1985-1990. Oxford: Oxford University Press 1990; 17.
6. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-942.
7. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
8. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-410.
9. Brincker H, Mouridsen HT, Andersen KW. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat 1983; 3: 91-95.
10. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-1729.
11. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990; 1: 183-188.
12. Rutqvist LE, Cedermark B, Fornander T et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989; 7: 1474-1484.
13. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
14. Crivellari K, Bonetti M, Castiglione-Gersch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluourouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol; 2000; 18: 1412-1422.
15. Rivkin SE, Green S, Metch B et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a South West Oncology Group study. J Clin Oncol 1994; 12: 2078-2085.
16. Pritchard KI, Paterson AMG, Fine S et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer. A report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 2302-2311.
17. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-1682.
18. Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-1018.
19. Albain K, Green S, Ravdin P et al. Overall survival after cyclophosphamide, adriamycin and 5-FU, and tamoxifen (CAFT) is superior to tamoxifen alone in postmenopausal, receptor (+), node (+) breast cancer: New findings from phase III Southwest Oncology Group Intergroup trial S8814 (INT-0100). Proc Am Soc Clin Oncol 2001; 20: 24a (Abstr 94).
20. Wils JA, Bliss JM, Marty M et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999; 17: 1988-1998.
21. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341: 418-422.
22. Goldhirsch A, Coates AS, Colleoni M et al. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol 1998; 16: 1358-1362.
23. Engelsman E, Klijn JC, Rubens RD et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: an EORTC Breast Cancer Cooperative Group phase III trial. Eur J Cancer 1991; 27: 966-970.
24. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679-688.
25. Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. An Italian multicentre trial. J Clin Oncol 1988; 6: 976-982.
26. Lopez M, Papaldo P, Di Lauro L et al. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) versus 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 1989; 46: 1-5.
27. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611.
28. Piscart MJ, Di Leo A, Beaudoin M et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001; 19: 3103-3109.
29. Wallgren A, Bernier J, Gelber RD et al. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys 1996; 35: 649-659.
30. Recht A, Come SE, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early stage breast cancer. N Engl J Med 1996; 334: 1356-1361.
31. Goldhirsch A, Gelber RD, Price KN et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994; 343: 377-381.
32. Grogan M, Tabar L, Chua B et al. Estimating the benefits of adjuvant systemic therapy for women with early breast cancer. Br J Surg 2001; 88: 1513-1518.
33. Hurny C, Bernhard J, Coates AS et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 1996; 347: 1279-1284.